New bronchodilators in treatment of chronic obstructive pulmonary disease

Baran BALCAN

ABSTRACT
Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Clinical diagnosis of COPD should be considered in any individual, who has dyspnea, chronic cough, sputum production, and positive history of risk factors. Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. After cessation of smoking and lifestyle modification, bronchodilator therapy is the first step in COPD treatment. Beside commonly used bronchodilator therapy newly developed bronchodilators started to be preferred. These drugs consist of long-acting beta2 agonist (Indacaterol, Vilanterol, Olodaterol, Abediterol), long acting muscarinic antagonism (Umeclidinium), long-acting beta2 agonist with inhaled steroid (combination of fluticasone furoate and vilanterol), long-acting beta2 agonist with a long-acting muscarinic antagonist (Fixed-dose combination of indacaterol with glycopyrronium by means of brezhaler device).

Keywords: Pulmonary disease, Chronic obstructive, Bronchodilator agents

Introduction
Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases [1]. Prevalence, morbidity and mortality of COPD vary across countries and different groups in the same country [2]. Prevalence of COPD is higher in male population in urban areas and the leading cause is tobacco smoking; on the other hand it is higher in female population in rural areas and the leading cause is biomass exposure [3]. Clinical diagnosis of COPD should be considered in any individual, who has dyspnea, chronic cough, sputum production, and positive history of risk factors [1]. This clinical context plus spirometric result (post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC) ratio %70) confirms the diagnosis of COPD4. Next step is the classification of the disease according to the severity of airflow limitation. The goal of COPD assessment is determining the severity of disease in order to guide the treatment [4]. Besides the severity of airflow limitations people classified according to their risk of hospitalization and severity of symptoms. Patient Group A: Low Risk, Less Symptoms, Group B: Low Risk, More Symptoms, Group C: High Risk, Less Symptoms, and Group D: High Risk, More Symptoms.

Steps of COPD treatment
- Smoking cessation; pharmacotherapy and nicotine replacement
- Pharmacologic therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance.
- Pharmacological treatment needs to be patient-specific;
guided by severity of symptoms, risk of exacerbations, drug availability, and the patient’s response.

- Influenza and pneumococcal vaccination should be offered to every COPD patient.
- Non-surgical bronchoscopic lung volume reduction techniques

**Pharmacotherapy**

- **Bronchodilators**
  - Long acting β2 agonist and anticholinergics are preferred to short acting ones.
  - If symptoms are not improved with single agents, combination therapies should be considered.
  - Inhaled bronchodilators are preferred to oral agents.

- **Corticosteroids**
  - Long term inhaled corticosteroid treatment is preferred in patients who have severe airflow limitation, and in patients who has frequent exacerbations despite use of long acting β2 agonist.
  - Long term monotherapy with oral steroids is not recommended
  - Long term single inhaled corticosteroid therapy is not recommended, instead combination with long acting β2 agonist with inhaled steroid is preferred.

**Newly developed bronchodilators**

*Long-acting beta2 agonist (LABA)*

Indacaterol, is a novel, once daily used, long acting beta2 agonist drug. Potency of this molecule is not as effective as formoterol or salmeterol but its potency is more than albuterol. It quickly onsets its bronchodilation action, and it has a longer duration of action when compared with these three molecules. One important advantage of indacaterol is once daily use due to its longer duration of action [5]. It has not more side effects on cardiovascular, or respiratory system, when compared to other LABAs [6].

Vilanterol (GW642444), a novel LABA used via inhalation [7]. In a randomized placebo controlled study 602 COPD patients were evaluated. Patients were randomized (double-blind) to vilanterol 3, 6.25, 12.5, 25, or 50 μg or placebo once daily for 28 days. At the end of the 4th week, improvement in the pulmonary functions is dose dependent and vilanterol 25, or 50μg leads to statistically significant improvement in FEV1 values [8].

Olodaterol (BI1744CL) is a novel, once-daily used LABA developed with the aim of improving β2-adrenoreceptor selectivity and intrinsic activity. Phase III pivotal trials have documented that olodaterol Respimat Soft Mist inhaler 5μg induces fast onset of bronchodilation, comparable with formoterol at day 1. Moreover, significant lung function improvements have been documented up to 48 weeks in patients with moderate to very severe COPD [9].

Abediterol is a different LABA which was compared with other LABAs et including indacaterol, olodaterol, vilanterol in vivo by Aparici. Abediterol has higher potency than other molecules in bronchodilation, its half life is longer than vilanterol but less than indacaterol and olodaterol [10]. All these novel drugs are alternative treatments in especially early stages of COPD.

*Long acting muscarinic antagonism (LAMA)*

Umeclidinium, a blocker of muscarinic subtype (M3) receptor, decreases the airway tone and improves the lung function. This molecule was compared with thiotropium in vivo, and it was shown that it blocked Ach-induced bronchoconstriction with longer duration of action. They suggest that umclidinium can be used once a daily in the treatment of COPD [11].

These novel treatment options can be used especially in early stages of COPD, but better clinical outcomes can be achieved with combination of LABA with inhaler steroid, or combination of LABA with LAMA.

*Long-acting beta2 agonist with inhaled steroid*

Available inhaled corticosteroid/LABA combinations for COPD require twice-daily administration. The combination of fluticasone furoate (FF) and vilanterol (VI) is being developed in a novel dry powder inhaler for the treatment of COPD with the potential for once-daily dosing. Boscia et al compared outcomes in COPD patients; one group used FF/VI combination, and the other group used placebo. Results have shown clinically and statistically significant improvements over placebo in FEV1, and there was a significant improvement in pulmonary functions test results [12].

*Combining a LABA with a LAMA*

Fixed-dose combination of indacaterol 110 µg/ glycopyrronium 50 µg by means of breezhaler device
(QVA149) has been shown in a series of clinical trials to be as safe as the single components and placebo, and more effective than placebo and the single components with regard to lung function, symptoms, and patient-oriented outcomes [13]. In addition it has better outcomes in both pulmonary functions and clinical outcomes of patients when compared to twice daily salmeterol and fluticasone combination [13]. The ENLIGHTEN study compared QVA149 with placebo; there was satisfactory improvement of FEV1, most of patients reporting no daytime symptoms, they were able to perform usual daily activities, and they did not report night-time awakenings [14]. In SHINE study they compared QVA149 with not only placebo but also with thiotropium handihaler 18 µg. Similar to ENLIGHTEN study better outcomes achieved in improvement of FEV1, and symptoms of patients [15]. In ILLUMINATI study they compared QVA149 with salmeterol 50 µg/fluticasone 500 µg. In QVA149 group better spirometric results were achieved, but there was no difference between clinical outcome and improvement of symptoms [16].

References